Yes, conditionally. Removal of a lump that is symptomatic, suspected-malignant, or part of a workup for a mass with concerning features is a covered illness claim at every reviewed US carrier once the 14-day illness wait has cleared. The clause that catches buyers is the inverse: a lump assessed as benign and removed for cosmetic or owner-preference reasons is excluded at most reviewed carriers under the cosmetic-and-elective exclusion. The line between the two is the workup and the chart language at the time of the procedure.
The direct answer
A mast cell tumor diagnosis, a fine-needle-aspirate result returning concerning cytology, or any mass workup that produces a malignant or borderline assessment moves the lump into the illness category at every reviewed carrier. Embrace, Pets Best, Spot Pet Insurance, ASPCA Pet Health Insurance, Healthy Paws, Lemonade, and the rest of the reviewed set classify removal of a symptomatic or workup-confirmed mass the same way they classify any covered surgical procedure: at the chosen reimbursement rate after the deductible [ASPCA Pet Health Insurance: Coverage, 2026]. Trupanion covers a mass removal of this kind on its single accident-and-illness product against the per-condition lifetime deductible and the flat 90% payout [Trupanion: What isn't covered by a Trupanion policy, 2026-05].
The cosmetic-and-elective exclusion is the inverse line. A clean fine-needle-aspirate, an unworked-up lipoma the owner wants removed for cosmetic reasons, or a benign skin tag excised at a wellness visit reads as elective at most reviewed carriers and is excluded from the base policy. The exclusion sits alongside other elective categories (declawing, dewclaw removal on a healthy adult, ear cropping) on the same shared-exclusion list across the reviewed set [Embrace: What's Covered and What's Not, 2026].
Where the policy clauses bite
The decisive document on a lump-removal claim is the workup and the chart language. A fine-needle aspirate or excisional biopsy that produces a malignant, borderline, or suspicious assessment establishes the illness-category coverage path. A clean cytology result on a routine lipoma, combined with a chart note that frames the removal as cosmetic or owner-preference, sits in the exclusion category.
Mast cell tumor or other malignancy on workup: covered as an illness claim at every reviewed carrier, paid at the chosen reimbursement rate after the deductible [ASPCA Pet Health Insurance: Coverage, 2026]. Symptomatic or fast-growing mass with a concerning workup: covered as an illness claim against the same structure. Benign lipoma removal for cosmetic or owner-preference reasons: excluded at most reviewed carriers under the cosmetic-and-elective exclusion [Embrace: What's Covered and What's Not, 2026]. Lump on a pre-existing chart: excluded for life at every reviewed carrier under the NAIC Pet Insurance Model Act standardized definition if the chart records the lump before the policy date or during a waiting period [NAIC: NAIC Passes Pet Insurance Model Act, 2022].
The surprise on a lump-removal claim is rarely the malignancy case; it is the assumed-benign case that turns out to be malignant on histopathology. A buyer who scheduled a routine lipoma removal expecting an out-of-pocket cosmetic bill, and whose post-removal histopathology returns a mast cell tumor diagnosis or other malignancy, can typically claim the procedure as an illness expense after the fact at most reviewed carriers, with the histopathology report as the supporting document. The carrier-by-carrier handling of this case varies; Embrace, Pets Best, and Spot are typically the most reasonable on accepting a post-removal histology reclassification.
The second surprise is the pre-existing line on lumps. A dog with a documented mass on the chart at enrollment carries that lump forward as pre-existing at every reviewed carrier. The full mast cell tumor claim category, on a dog with a prior mast cell tumor diagnosis at the time of a carrier switch, is excluded as pre-existing on the new policy under the standard exclusion [NAIC: NAIC Passes Pet Insurance Model Act, 2022].
What this means for you
For a buyer of a clean-chart dog or cat with no documented lumps at enrollment, the lump-removal claim category behaves like any other illness category in the reviewed set: the 14-day illness wait clears the first claim, the policy pays the chosen reimbursement rate after the deductible on covered removals, and the annual cap is the binding constraint on a complication-driven case. Mast cell tumors and other malignancies route through the same cancer-claim mechanics the policy uses for any malignancy, with the annual cap as the load-bearing variable on a multi-stage course; the full cancer-claim mechanic is at cancer.
For a buyer with a dog that has a documented lipoma or skin mass at the chart, the new policy excludes that specific lump and the broader mast cell tumor or skin-tumor category from coverage at most reviewed carriers. The mechanic for the elective-removal exclusion that covers benign lipomas without a workup is at what isn't covered, and the pre-existing rule is at pre-existing conditions. The review method is at /methodology/.
Bottom line
The decisive variable on a lump-removal claim is the workup, the chart language, and the timing relative to enrollment. A workup-confirmed malignancy on a clean-chart pet is one of the conditions the policy is designed to cover. A routine benign lipoma removal on the same pet is one of the conditions the policy is designed to exclude.